\

Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Press Releases

Get News Alerts by Email

May 6, 2020

Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer

- New corporate name, Cardiff Oncology, reflects the Company's mission and commitment to turning the tide on cancer by developing new treatment options for cancer patients
Apr 28, 2020

Onvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes and Durable Response

- Ongoing Phase 1b/2 trial has enrolled 12 patients with 88% response in 7 of 8 evaluable patients; to-date 3 patients with a partial response (PR); 4 patients with stable disease (SD)
Apr 22, 2020

Trovagene Expands Board with Addition of Three Industry Leaders - James Armitage, MD, Lâle White, and Gary Pace, PhD
Apr 8, 2020

Trovagene to Present at the 19th Annual Needham Healthcare Conference
Apr 1, 2020

Trovagene Announces Acceptance of Phase 1b/2 KRAS-Mutated Metastatic Colorectal Cancer (mCRC) Trial Abstract for Presentation at the 2020 ASCO Annual Meeting

Show per page